This paper is only available as a PDF. To read, Please Download here.
Abstract
Neuroleptic malignant syndrome is a potentially fatal consequence of neuroleptic use
that has recently gained wide attention. In this article the authors critically review
the previous literature and analyze all case reports in the English-language literature
(115 cases) for 43 variables. The results are discussed in light of prior literature,
and recommendations are made for future research.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neuroleptic malignant syndrome.Br J Psychiatry. 1986; 148: 47-51
- Rapid induction of extrapyramical side effects with combined use of lithium and neuroleptics.J Clin Psychopharmacol. 1985; 5: 296-298
- Neuroleptic malignant syndrome and use of anesthetic agents.Am J Psychiatry. 1986; 143: 127-128
- ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome.J Clin Psychiatry. 1986; (in press).
- Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients.Am J Psychiatry. 1986; 143: 1587-1590
- The aftercare of the patient with the neuroleptic malignant syndrome.Br J Psychiatry. 1985; 146: 317-318
- The neuroleptic malignant syndrome: Do we know enough?.Jefferson J Psychiatry. 1985; 3: 45-49
- Side effects of parenteral long-acting phenothiazines.Br Med J. 1972; 1: 221
- A therapeutic trial of amantadine in haloperidol-induced malignant neuroleptic syndrome.Curr Ther Res. 1983; 33: 225-229
- Adverse reactions in treatment with lithium carbonate and haloperidol.JAMA. 1976; 236: 2645-2646
- Malignant neuroleptic syndrome: An atypical case.Psychosomatics. 1979; 20: 840-846
- Detection and management of the neuroleptic malignant syndrome.Clin Pharmacol. 1984; 3: 302-307
- Malignant hyperthermia: A statistical review.Can Anaesthesiol Soc J. 1970; 17: 293-315
- Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease.Neurology (NY). 1981; 31: 1022-1026
- Calcium and malignant catatonia.Lancet. 1977; ii: 1124-1125
- The neuroleptic malignant syndrome.J Clin Psychiatry. 1980; 41: 79-83
- Neuroleptic malignant syndrome and malignant hyperthermia.J Clin Psychopharmacol. 1983; 3: 120
- Neuroleptic malignant syndrome and malignant hyperthermia.Lancet. 1983; i: 244
- Occurrence of neuroleptic malignant syndrome in a narcoleptic patients.Hosp Commun Psychiatry. 1983; 34: 548-550
- Lithium carbonate, haloperidol, and irreversible brain damage.JAMA. 1974; 230: 1283-1287
- Treatment of neuroleptic malignant syndrome with dantrolene sodium: A case report.Am J Psychiatry. 1982; 139: 944-945
- Neuroleptic malignant syndrome after haloperidol therapy.South Med J. 1983; 76: 684-686
- Drug-induced extrapyramidal syndromes.in: Handbook of Clinical Neurology: Diseases of the Basal Ganglia. vol 6. Elsevier/North Holland, New York1968: 248-266
- Un neuroleptique majeur non phenothiazinique et non reserpinique, l'haloperidol, dans le traitement des psychoses.Ann Med Phychol. 1960; 118: 145-152
- L'emploi des butyrophenones en psychiatrie: Etude statistique et psychometrique.in: Symposium Internazionale Sull' Haloperidol E Triperidol, Milano1962: 305-319
- Treatment of the neuroleptic malignant syndrome with bromocriptine.JAMA. 1983; 250: 484-485
- Parenteral long-acting phenothiazines.Br Med J. 1972; 1: 807
- Neuroleptic malignant syndrome: patient with unique clinical and physiologic features.Am J Med. 1984; 77: 338-340
- Neuroleptic malignant syndrome.Med J Aust. 1984; 141: 198-199
- Acute myoglobinuric renal failure a consequence of the neuroleptic malignant syndrome.Arch Intern Med. 1982; 142: 601-603
- Neuroleptics, extrapyramidal symptoms, and serum calcium levels.Compr Psychiatry. 1984; 25: 539-545
- Neuroleptic malignant syndrome associated with loxapine.J Clin Psychiatry. 1983; 44: 37-38
- Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: A case report.Am J Psychiatry. 1981; 138: 1115-1116
- Hyperthermia after discontinuance of levodopa and bromocriptine therapy: Impaired dopamine receptors a possible cause.Neurology. 1985; 35: 258-261
- Neuroleptic catatonia and its relationship to psychogenic catatonia.Biol Psychiatry. 1985; 20: 304-313
- Intravenous lorazepam in neuroleptic-induced catatonia.J Clin Psychopharmacol. 1983; 3: 338-342
- A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal.JAMA. 1985; 254: 2792-2795
- Amantadine in the neuroleptic malignant syndrome.J Clin Psychiatry. 1984; 45: 526
- Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: Two case reports with a literature review.J Clin Psychiatry. 1979; 40: 102-103
- Pridinolum mesylate and neuroleptic malignant syndrome.Am J Psychiatry. 1985; 142: 389-390
- Treatment of neuroleptic malignant syndrome with dantrolene.Lancet. 1982; ii: 49-50
- Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: A report of two cases.Neurology. 1983; 33: 516-518
- Neuroleptic malignant syndrome: Successful treatment with dantrolene and bromocriptine.Ann Neurol. 1983; 14: 89-90
- Neuroleptic malignant syndrome.Br Med J. 1984; 288: 1690
- The neuroleptic malignant syndrome: Review and report of three cases.Compr Psychiatry. 1985; 26: 63-70
- Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal.J Clin Psychiatry. 1978; 39: 673-675
- Neuroleptic malignant syndrome due to depot fluphenazine.J Clin Psychiatry. 1979; 40: 99-100
- Neuroleptic malignant syndrome.N Engl J Med. 1985; 313: 163-166
- Malignant hyperthermia—An allergic reaction to thioridazine therapy.Arch Intern Med. 1978; 138: 800-801
- Neuroleptic malignant syndrome and dopaminergic blockade.Arch Intern Med. 1984; 144: 629-630
- Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade?.Neurology (NY). 1981; 31: 132-137
- Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: The possible role of D-2 dopamine receptors.J Nerv Ment Dis. 1984; 172: 692-695
- ECT during and after the neuroleptic malignant syndrome: Case report.J Clin Psychiatry. 1986; 47: 42-43
- The neuroleptic malignant syndrome: A case report.Int J Psychiatry Med. 1982; 12: 43-47
- Malignant neuroleptic syndrome—Its present status in Japan and clinical problems.Folia Psychiatr Neurol Jpn. 1977; 31: 559-576
- The question of lithium/neuroleptic toxicity.Can J Psychiatry. 1984; 29: 601-604
- ECT in the neuroleptic malignant syndrome: Case report.J Clin Psychiatry. 1983; 44: 186-188
- Resolution of neuroleptic malignant syndrome with dantrolene sodium: Case report.J Clin Psychiatry. 1985; 46: 244-246
- Neuroleptic malignant syndrome.Med J Aust. 1984; 140: 28-30
- Neuroleptic malignant syndrome induced by a single injection of haloperidol.Br Med J. 1984; 289: 1228-1229
- Neuroleptic malignant syndrome.Clin Neuropharmacol. 1984; 7: 109-120
- Neuroleptic malignant syndrome and amantadine withdrawal.Am J Psychiatry. 1985; 142: 142
- Neuroleptic malignant syndrome: Detection and management.Psychiatr Ann. 1985; 15: 706-712
- Neuroleptic malignant syndrome.Am J Psychiatry. 1985; 142: 1137-1145
- Neuroleptic-induced extrapyramidal symptoms with fever—heterogeneity of the neuroleptic malignant syndrome.Arch Gen Psychiatry. 1986; 43: 839-848
- Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.Biol Psychiatry. 1983; 18: 1441-1446
- General anesthesia after neuroleptic malignant syndrome.Biol Psychiatry. 1983; 18: 243-247
- Neuroleptic malignant syndrome: Response to dantrolene sodium.Ann Intern Med. 1983; 98: 183-184
- Fever, tachycardia, and hypertension with acute catatonic schizophrenia.Arch Intern Med. 1978; 138: 1154-1156
- A case of neuroleptic malignant syndrome successfully treated with amantadine.J Clin Psychiatry. 1982; 43: 381-382
- Rigidity, hyperpyrexia and coma following fluphenazine enanthate.Psychopharmacologia. 1973; 29: 337-346
- Neuromuscular dysfunction in schizophrenia.Schizophren Bull. 1976; 2: 106-135
- Atypical neuroleptic malignant syndrome responsive to conservative management.Psychosomatics. 1985; 26: 62-66
- Neuroleptic malignant syndrome.Arch Neurol. 1980; 37: 462-463
- Neuroleptic malignant syndrome—Successful treatment with bromocriptine.JAMA. 1983; 249: 386-388
- The malignant hyperthermia syndrome.N Engl J Med. 1983; 309: 416-418
- Neuroleptic malignant syndrome: A review of the literature.J Clin Psychopharmacol. 1986; 6: 257-273
- Catatonic behavior, viral encephalopathy, and death.Arch Gen Psychiatry. 1972; 27: 758-761
- Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital.Am J Psychiatry. 1986; 143: 1227-1233
- Apparent neuroleptic malignant syndrome with clozapine and lithium.J Nerv Ment Dis. 1986; 174: 493-495
- Hyperpyrexia in catatonic states.Dis Nerv Syst. 1976; 37: 359-361
- A paradoxical response to chlorpromazine—A possible variant of the neuroleptic malignant syndrome.J Clin Pharmacol. 1983; 23: 567-569
- Sudden catatonic stupor with disastrous outcome.JAMA. 1977; 238: 618-620
- Dopamine agonists and neuroleptic malignant syndrome.Am J Psychiatry. 1985; 142: 270-271
- Diagnosing and treating neuroleptic malignant syndrome.Am J Psychiatry. 1986; 143: 673
- Malignant neuroleptic syndrome due to haloperidol.J Postgrad Med. 1983; 29: 56-58
- Neuroleptic malignant syndrome—Successful treatment with pancuronium.JAMA. 1985; 254: 2795-2796
- Neuroleptic malignant syndrome.Aust NZ J Med. 1983; 13: 70-73
- A role for catecholamines in the pathogenesis of neuroleptic malignant syndrome.Can J Psychiatry. 1986; 31: 66-69
- The neuroleptic malignant syndrome.Med J Aust. 1981; 2: 494
- Fatal hyperpyrexia after withdrawal of levodopa.Neurology. 1984; 34 (Cleveland): 249-251
- The neuroleptic malignant syndrome: Agent and host interaction.Acta Psychiatr Scand. 1986; 73: 337-347
- Gas-producing Escherichia coli fasciitis in a patient with the neuroleptic malignant syndrome.JAMA. 1983; 250: 361
- Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine.Am J Psychiatry. 1984; 141: 796-797
- The neuroleptic malignant syndrome.Arch Intern Med. 1982; 142: 1183-1185
- Neuroleptic malignant syndrome with a positive Weil-Felix test.Am J Psychiatry. 1984; 141: 609
- New data on lithium and haloperidol incompatibility.Am J Psychiatry. 1981; 138: 818-821
- The differential diagnosis of catatonic states.Psychosomatics. 1982; 23: 245-252
- Neuroleptic malignant syndrome and neuroleptic-induced catatonia: Differential diagnosis and treatment.Int J Psychiatry Med. 1984; 14: 57-63
- Reinduction of neuroleptic malignant syndrome by lithium.J Clin Psychopharmacol. 1987; (in press).
- A case of neuroleptic malignant syndrome: In vitro muscle comparison with malignant hyperthermia.J Clin Psychopharmacol. 1982; 2: 266-270
- The neuroleptic syndrome and central dopamine metabolites.J Clin Psychopharmacol. 1984; 4: 150-153
- Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.J Nerv Ment Dis. 1981; 169: 324-327
- Neuroleptic malignant syndrome—Association with thioridazine hydrochloride in a manic depressive patient.J Kans Med Soc. 1983; 84: 523-533
- Neuroleptic malignant syndrome: Successful treatment with bromocriptine.Biol Psychiatry. 1985; 20: 680-684
- Neuroleptic malignant syndrome and hyponatraemia.Lancet. 1984; i: 963
- Neuroleptic malignant syndrome.Anesth Analg. 1983; 62: 848-850
- Catalonia and malignant syndrome: A possible complication of neuroleptic administration.J Nerv Ment Dis. 1977; 165: 263-268
- Management of a case of neuroleptic malignant syndrome with bromocriptine.Am J Psychiatry. 1983; 140: 1619-1620
Article info
Publication history
Received in revised form:
November 22,
1986
Received:
September 30,
1986
Identification
Copyright
© 1987 Published by Elsevier Inc.
